Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. Recommendations on the use of 18F-FDG PET in oncology 3. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials 4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer 5. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ
Top Ten Searches
brca1 prostate-specific antigen sclc fobt egd bmi dysplasia hematologic ovarian hccYour Article Summary
See Latest ArticlesEfficacy of sequential high-dose doxorubicin and ifosfamide compared with standard-dose doxorubicin in patients with advanced soft tissue sarcoma: An open-label randomized phase II study of the Spanish Group for Research on Sarcomas
Journal of Clinical Oncology, 04/13/09
Maurel J et al. - Study reports that single-agent doxorubicin remains the standard treatment in fit patients with advanced soft tissue sarcoma.
Methods- Aim was to assess the progression-free survival (PFS) and antitumor response to standard-dose doxorubicin vs sequential dose-dense doxorubicin and ifosfamide
- Pts (n=132) with performance status (PS) <2, ages 18-65 yrs, and with adequate bone marrow, liver, and renal function were enrolled
- The stratifications were: ECOG PS (0 v 1), location of metastases, and potentially resectable disease
- Patients were randomly assigned to either:
- Arm A: doxorubicin 75 mg/m2 given as a bolus injection every 3 wks for 6 cycles or
- Arm B: doxorubicin at 30 mg/m2/d for 3 consecutive days x1/ 2 wks for 3 cycles followed by ifosfamide at 12.5 g/m2 delivered by continuous infusion over 5 days x1/ 3 wks for 3 cycles with filgastrim or pegfilgastrim support
- Febrile neutropenia, asthenia, and mucositis were more frequent in the arm B
- The interim preplanned analysis for futility allowed the premature closure
- Objective responses were observed in 23.4% of assessable pts in arm A and 24.1% in arm B
- PFS was 26 wks in the arm A and 24 wks in arm B
- Overall survival did not differ between the two therapeutic arms
Today in Pharmacology/Therapy...keeping you current
Receive free subspecialty "5-minute updates" via email
Clinical Benefit of Allogeneic Melanoma Cell Lysate–Pulsed Autologous Dendritic Cell Vaccine in MAGE-Positive Colorectal Cancer Patients
Clinical Cancer Research, 12/11/09
Radiation Therapy for Rectal Cancer: Current Status and Future Directions
Cancer Control, 12/11/09
Current Progress in Targeted Therapy for Colorectal Cancer
Cancer Control, 12/11/09
Today in Soft Tissue/Sarcoma...keeping you current
Receive free subspecialty "5-minute updates" via email
Immunoprofile of mesenchymal chondrosarcoma: aberrant desmin and EMA expression, retention of INI1, and negative estrogen receptor in 22 female-predominant central nervous system and musculoskeletal cases
Annals of Diagnostic Pathology, 12/11/09
Birth characteristics and the risk of childhood rhabdomyosarcoma based on histological subtype
British Journal of Cancer, 12/11/09
HER-2 targeted treatment of osteosarcoma: the challenges of developing targeted therapy and prognostic factors for rare malignancies
Expert Opinion in Pharmacotherapy, 12/11/09
Sponsor
Article Search
Sponsor
Sponsor